GNBT - Generex updates the COVID-19 vaccine program

Announcing the filing for a trademark for The Complete Vaccine™, Generex Biotechnology ([[GNBT]] +28.9%), says it has made significant progress in the li-Key-SARS-CoV-2 vaccine program.Generex's majority-owned public entity, NuGenerex Immuno-Oncology, has completed the T Cell assays and HLA typing of blood samples taken from 46 convalescent COVID-19 patients and 30 healthy pre-COVID donors.The screening of the immune regulatory activity of 33 Ii-Key epitopes has demonstrated that numerous Ii-Key epitopes activated CD4+ Th1 and CD8+ responses and none of the Ii-Key epitopes tested activated any negative Th2 responses.Ii-Key epitopes have been used to bind and purify IgG antibodies from convalescent COVID-19 patient samples, The antibodies are undergoing tests to ensure their neutralizing effect on the SARS-CoV-2 virus, and once confirmed, Ii-Key epitope binding antibodies can be purified and genetically engineered to develop antibody therapeutics against COVID-19, the company said in a statement.Generex has already commenced the GMP production of several Ii-Key-SARS-CoV-2

For further details see:

Generex updates the COVID-19 vaccine program